A Phase II combination study of ARGX-110 with the standard of care in acute myeloid leukemia.
Phase of Trial: Phase II
Latest Information Update: 08 Oct 2016
At a glance
- Drugs ARGX 110 (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 08 Oct 2016 New trial record
- 22 Sep 2016 According to an arGEN-X media release, company plans to initiate this study before the end of the year 2016.